Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.34 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933673 | 0.90 | ATP4A (0.40) | MEN1KMT2AHRH3ATP4AATP4B | |
| SCHEMBL16933698 | 0.89 | JAK2 (0.41) | ACKR3CHRM5CHRM1CHRM3HRH3 | |
| SCHEMBL16933481 | 0.84 | CHRM5 (0.40) | MEN1KMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL16933479 | 0.84 | CHRM5 (0.40) | MEN1KMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL16933687 | 0.83 | CHRM5 (0.42) | MEN1KMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL16933523 | 0.81 | CHRM5 (0.40) | MEN1KMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL15579458 | 0.80 | PRKAB2 (0.37) | MEN1KMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL16933531 | 0.79 | GPR119 (0.41) | MEN1KMT2ACHRM5CHRM1CHRM3 | |
| SCHEMBL29387708 | 0.78 | NTMT1 (0.49) | — | |
| SCHEMBL16933618 | 0.77 | FLT3 (0.36) | CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | ACKR3 2927/4885MEN1 1532/4885KMT2A 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.